A need to revise ciprofloxacin breakpoints for Salmonella in human beings.
Varsha
V
Gupta
Jaspal
J
Kaur
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards*; D010284:Paratyphoid Fever / Q000188:drug therapy / Q000382:microbiology; D012482:Salmonella paratyphi A / Q000187:drug effects*; D012485:Salmonella typhi / Q000187:drug effects*; D014435:Typhoid Fever / Q000188:drug therapy / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin